{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.7","upperLimit":"98.0","value":"94.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"description":"Complete Cytogenetic Response (CCyR) rate is defined as the proportion of all treated participants who achieve a CCyR while on-study, expressed as a percentage. CCyR rate is defined as 0% Ph+ metaphases in at least 20 metaphases in bone marrow. The denominator of the CCyR response rate consists of all treated participants in Cohort 3, and the numerator is all participants in Cohort 3 achieving CCyR. 95% confidence interval was calculated by Clopper-Pearson exact method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 3"}],"paramType":"NUMBER","populationDescription":"Primary efficacy endpoint pre-specified only for participants treated in Cohort 3","reportingStatus":"POSTED","timeFrame":"From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)","title":"Complete Cytogenetic Response (CCyR) Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}